Sarpogrelate hydrochloride

Cat. No.: HY-10564  
CAS No.: 135159-51-2  
Molecular Formula: C₂₄H₃₂ClNO₆  
Molecular Weight: 465.97  
Target: 5-HT Receptor  
Pathway: GPCR/G Protein; Neuronal Signaling  
Storage:  
- Powder: -20°C for 3 years, 4°C for 2 years, In solvent: -80°C for 6 months, -20°C for 1 month

Solvent & Solubility

In Vitro  
DMSO : ≥ 62 mg/mL (133.06 mM)  
* “≥” means soluble, but saturation unknown.

<table>
<thead>
<tr>
<th>Preparing Stock Solutions</th>
<th>Concentration</th>
<th>1 mg</th>
<th>5 mg</th>
<th>10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1 mM</td>
<td>2.1461 mL</td>
<td>10.7303 mL</td>
<td>21.4606 mL</td>
</tr>
<tr>
<td></td>
<td>5 mM</td>
<td>0.4292 mL</td>
<td>2.1461 mL</td>
<td>4.2921 mL</td>
</tr>
<tr>
<td></td>
<td>10 mM</td>
<td>0.2146 mL</td>
<td>1.0730 mL</td>
<td>2.1461 mL</td>
</tr>
</tbody>
</table>

BIOLOGICAL ACTIVITY

Description  
Sarpogrelate(MCI-9042) hydrochloride, a selective 5-HT2 antagonist, has been widely used as an anti-platelet agent for the treatment of PAD. Target: 5-HT2 Receptor. Sarpogrelate is a drug which acts as an antagonist at the 5HT2A and 5-HT2B receptors. Sarpogrelate was shown to have the same affinity as ritanserin for 5-HT2A receptors, with a Ki value of 8.39 nM [1]. Sarpogrelate lacked prominent 5-HT1-like, 5-HT3, beta, H1, H2 and M3 antagonist activity and weakly blocked alpha 1-adrenoceptors (pKB = 6.80). (S)-M-1 showed weak affinity for 5-HT1-like receptors (pKB = 6.30), alpha 1- (pKB = 6.80) and beta- (pKB = 6.54) adrenoceptors, while (R)-M-1 was a weak antagonist at histamine H1 receptors (pKB = 6.49) [2]. After 12 weeks of sarpogrelate administration, FBF and LBF responses during RH showed significant increases from 13.2 +/- 1.7 to 18.1 +/- 2.2 mL/min per 100 mL tissue (P < 0.01) and from 8.2 +/- 0.9 to 14.2 +/- 2.1 mL/min per 100 mL tissue (P < 0.05), respectively. Sarpogrelate-induced augmentation of FBF and LBF responses to RH was maintained at 24 weeks. Long-term oral administration of sarpogrelate improves vascular function in patients with PAD [3].
REFERENCES


Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA